,31 Dupilumab, a fully human monoclonal antibody inhibits both IL-4 and IL-13 signaling, has been shown to be significantly effective in the treatment of subjects with persistent, moderate-to-severe asthma and a blood eosinophil count ≥0.3 × 109/L or sputum eosinophils ≥3%.32 The gene discussed is IL13; the disease is asthma.